{"id":"W4386755083","doi":"10.33590/emj/10308910","title":"Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition","year":2023,"lang":"en","type":"article","venue":"European Medical Journal","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Esperion Therapeutics; HLS Therapeutics; Servier; Duke Clinical Research Institute; Novo Nordisk; Regeneron Pharmaceuticals; York University; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Idorsia Pharmaceuticals; University of Toronto; Cleveland Clinic; Alnylam Pharmaceuticals; Pfizer; Heart and Stroke Foundation of Canada; Daiichi Sankyo Europe; American Regent; Sanofi; Amgen","keywords":"Medicine; Intensive care medicine; Rivaroxaban; Population; Warfarin; Discovery and development of direct thrombin inhibitors; Regimen; Anticoagulant; Atrial fibrillation; Apixaban; Clinical trial; Thrombosis; Major bleeding; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01377439,0.0009217405,0.001109337,0.001106867,0.001204277,0.005342503,0.001249475,0.004388903,0.005524243],"category_scores_gemma":[0.01961758,0.0002947199,0.001102656,0.0006810676,0.002731701,0.005874716,0.002884578,0.01284885,0.001403656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003053307,"about_ca_system_score_gemma":0.007355509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004270373,"about_ca_topic_score_gemma":0.007720741,"domain_scores_codex":[0.9949487,0.001630751,0.0003300096,0.0003991905,0.001984439,0.0007069055],"domain_scores_gemma":[0.9826832,0.008202015,0.0008567285,0.0004151536,0.004579236,0.003263735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002768014,0.0002384335,0.0009075953,0.001277354,0.00008281582,0.0002206723,0.001063819,0.0002598108,0.001345306,0.01508766,0.3619377,0.617302],"study_design_scores_gemma":[0.0001587509,0.0007700124,0.002451483,0.002775033,0.00008501191,0.0005378548,0.0006712399,0.0004912416,0.0009759663,0.01500712,0.9759892,0.0000871407],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.002621192,0.2831282,0.001767964,0.673023,0.02851301,0.00004513703,0.00007101471,0.00009184561,0.01073873],"genre_scores_gemma":[0.04443786,0.5888649,0.0086002,0.2445481,0.09307531,0.0001221522,0.0002723849,0.0001368216,0.01994229],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01377439,"threshold_uncertainty_score":0.07284683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02770444359575574,"score_gpt":0.2790438000973046,"score_spread":0.2513393565015489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}